Seeyond lowered its stake in Stryker Co. (NYSE:SYK) by 17.9% during the second quarter, Holdings Channel reports. The firm owned 3,645 shares of the medical technology company’s stock after selling 796 shares during the period. Seeyond’s holdings in Stryker were worth $749,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of SYK. FMR LLC grew its position in Stryker by 13.4% in the first quarter. FMR LLC now owns 6,728,182 shares of the medical technology company’s stock valued at $1,328,951,000 after acquiring an additional 793,560 shares during the last quarter. Geode Capital Management LLC grew its position in Stryker by 6.5% in the fourth quarter. Geode Capital Management LLC now owns 3,665,205 shares of the medical technology company’s stock valued at $573,387,000 after acquiring an additional 224,785 shares during the last quarter. GQG Partners LLC grew its position in Stryker by 24.8% in the first quarter. GQG Partners LLC now owns 924,369 shares of the medical technology company’s stock valued at $182,241,000 after acquiring an additional 183,802 shares during the last quarter. Janus Henderson Group PLC grew its position in Stryker by 16.0% in the second quarter. Janus Henderson Group PLC now owns 1,268,453 shares of the medical technology company’s stock valued at $260,765,000 after acquiring an additional 175,409 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its position in Stryker by 3,378.1% in the first quarter. Teacher Retirement System of Texas now owns 160,133 shares of the medical technology company’s stock valued at $31,629,000 after acquiring an additional 155,529 shares during the last quarter. Institutional investors own 73.01% of the company’s stock.

Shares of SYK stock traded down $0.94 during mid-day trading on Friday, reaching $219.10. 25,738 shares of the stock traded hands, compared to its average volume of 894,274. The stock’s fifty day simple moving average is $216.42 and its two-hundred day simple moving average is $199.39. Stryker Co. has a 1-year low of $144.75 and a 1-year high of $223.45. The company has a market cap of $82.34 billion, a price-to-earnings ratio of 30.07, a price-to-earnings-growth ratio of 2.59 and a beta of 0.83. The company has a quick ratio of 1.26, a current ratio of 2.07 and a debt-to-equity ratio of 0.67.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 25th. The medical technology company reported $1.98 EPS for the quarter, beating the Zacks’ consensus estimate of $1.93 by $0.05. The firm had revenue of $3.65 billion for the quarter, compared to analyst estimates of $3.60 billion. Stryker had a return on equity of 25.98% and a net margin of 24.99%. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period last year, the firm posted $1.76 earnings per share. On average, equities research analysts anticipate that Stryker Co. will post 8.21 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date is Friday, September 27th. Stryker’s dividend payout ratio is currently 28.45%.

A number of research analysts have issued reports on SYK shares. Wells Fargo & Co lifted their target price on Stryker from $219.00 to $228.00 and gave the company an “outperform” rating in a research report on Tuesday, July 2nd. Canaccord Genuity lifted their target price on Stryker from $195.00 to $233.00 and gave the company a “buy” rating in a research report on Friday, July 26th. BTIG Research set a $228.00 target price on Stryker and gave the company a “buy” rating in a research report on Thursday, September 5th. Credit Suisse Group lifted their target price on Stryker from $232.00 to $237.00 and gave the company an “outperform” rating in a research report on Friday, July 26th. Finally, Svb Leerink reiterated an “outperform” rating on shares of Stryker in a research report on Wednesday, July 10th. Five research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $214.89.

In related news, insider Timothy J. Scannell sold 4,666 shares of Stryker stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $205.88, for a total value of $960,636.08. Following the transaction, the insider now directly owns 155,963 shares of the company’s stock, valued at $32,109,662.44. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Srikant M. Datar sold 350 shares of Stryker stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $215.00, for a total value of $75,250.00. Following the completion of the transaction, the director now directly owns 6,844 shares in the company, valued at $1,471,460. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,447 shares of company stock worth $4,262,634. 7.20% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Article: What is a death cross?

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.